Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Olema Oncology (OLMA) to $22 from $25 and keeps an Outperform rating on the shares following quarterly results. Arguably, their biggest catalyst is later this year with the potential for early OP-3136 Phase 1 data, the firm notes.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals: Promising Pipeline and Strategic Trials Support Buy Rating
- Olema Pharmaceuticals: Promising Clinical Trials and Strategic Advancements Drive Buy Rating
- Olema Oncology reports Q1 EPS (36c), consensus (46c)
- OLMA Upcoming Earnings Report: What to Expect?
- Oncology stocks ‘bearing the brunt’ of Prasad news, says Oppenheimer